论文部分内容阅读
铋化合物用于临床治疗已有一个世纪,以往大多作为消化系疾病的症状治疗,不被人们重视。自从新型铋制剂胶体铋(colloidal bismuth)问世以来,铋化合物的临床应用有了新的突破,主要在消化性溃疡的治疗方面取得了显著效果。胶体铋又称三钾二枸橼酸铋(tripotassium dicitroto bismuthate,TDB)或称复方铋合剂(MBC),是构橼酸铋盐的复合物,其分子式如下:Bi_x(OH)_y(C_6H_5O_7)_z。 TDB和其他铋盐不同,具有较高的水溶性,在酸性条件下,pH<5发生沉淀。由于沉淀中含有游离的羧基和铋离子,对蛋白质具有高度亲和力。故可和溃疡基底坏死组织中的蛋白结合,形成复盖膜而发挥治疗作用。
Bismuth compounds have been used clinically for more than a century, mostly as a symptom of digestive diseases, and have not been taken seriously. Since the advent of the new colloidal bismuth, a bismuth compound, new breakthroughs have been made in the clinical application of bismuth compounds, which have achieved remarkable results mainly in the treatment of peptic ulcer. Colloidal bismuth, also known as tripotassium dicitroto bismuthate (TDB) or compound bismuth (MBC), is a complex of bismuth citrate salts of the formula: Bi_x (OH) _y (C_6H_5O_7) _z . Unlike other bismuth salts, TDB is highly water-soluble and precipitates at pH <5 under acidic conditions. Since the precipitate contains free carboxyl and bismuth ions, it has a high affinity for the protein. It can and ulcer basal tissue necrosis of the protein binding to form a cover film and play a therapeutic role.